NVIDIA Healthcare and Life Sciences Kimberly Powell | VP Healthcare and Life Sciences JP Morgan Health Conference 2025 Except for the historical information contained herein, certain matters in this presentation including, but not limited to, statements as to: our market opportunity; the benefits, impact, performance, features, and availability of our products and technologies including NVIDIA AI Agent Platform, NVIDIA AI Blueprints, NVIDIA NeMo, NVIDIA NIM, NVIDIA BioNeMo Platform, NVIDIA Clara, NVIDIA DGX ...

J.P. Morgan Healthcare Conference January 13, 2025 Safe Harbor Statement In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully launching CRENESSITY; our financial ...

Summary of Nuvation Bio's Conference Call Company Overview - **Company**: Nuvation Bio - **Focus**: Oncology, specifically targeting unmet needs with best-in-class drugs - **Key Products**: Taletrectinib (ROS1 inhibitor), Safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), NUV-868 (BET inhibitor) [3][4][63] Key Points Taletrectinib - **Indication**: Advanced ROS1+ NSCLC - **Approval Status**: Approved in China; NDA accepted by U.S. FDA for priority review with a PDUFA date of June 23, 2025 [3][5][68] - **Clinical Data**: - Highest overall response rate (ORR) of 89% and median progression-free survival (mPFS) of 46 months in TKI-naïve patients [6][7] - Compared to competitors, taletrectinib shows superior efficacy with a median duration of response (mDOR) of 44 months [6][7] - In the second line setting, taletrectinib also demonstrates a competitive ORR and mPFS [11][12] - **Market Opportunity**: - Estimated U.S. market opportunity of ~$3.8 billion based on 3,000 newly diagnosed patients annually at a price of ~$350,000 per year [21][25] - ROS1+ NSCLC market represents a significant commercial opportunity, with first-generation ROS1 TKIs generating ~$500 million in 2023 despite lower mPFS [17][21] Safusidenib - **Indication**: Diffuse IDH1-mutant glioma - **Development Status**: Entering pivotal studies in 2025 [40] - **Clinical Data**: Early-stage data shows higher response rates than vorasidenib in both low-grade and high-grade gliomas [50] - **Market Potential**: Approximately 13,300 to 18,300 people living with diffuse IDH1-mutant glioma in the U.S. [45] Financial Position - **Cash Balance**: Robust cash position of $549 million as of September 30, 2024, supporting near-term operations [3][65] - **Commercial Stage Potential**: Nuvation Bio is positioned to potentially become a U.S. commercial stage organization as early as mid-2025 [67] Regulatory and Competitive Landscape - **Regulatory Updates**: New NCCN guidelines contraindicate immunotherapy/chemotherapy and recommend ROS1 TKIs for ROS1+ NSCLC [26][30] - **Competitive Advantage**: Taletrectinib's efficacy and safety profile may provide a competitive edge over existing therapies in the ROS1+ NSCLC market [14][31] Additional Insights - **Management Team**: Led by Dr. David Hung, who has a successful track record in biotech [63] - **Pipeline Diversity**: Nuvation Bio has a broad pipeline across multiple stages of development, indicating a strong focus on innovation in oncology [66] This summary encapsulates the critical aspects of Nuvation Bio's conference call, highlighting the company's strategic focus, product pipeline, market opportunities, and financial health.

Key Points Industry/Company - **Company**: Biohaven Ltd. - **Industry**: Biotechnology, pharmaceuticals, rare diseases, neuroscience, oncology, immunology, inflammation, and obesity. Core Views and Evidence - **MoDE Platform**: Biohaven's MoDE platform utilizes targeted protein degradation technology to remove disease-causing proteins. This platform has the potential to treat a wide range of diseases, including rare diseases, neurological disorders, oncology, and immunology and inflammation-related conditions. - **Troriluzole**: Troriluzole is a treatment for Spinocerebellar Ataxia (SCA) that has demonstrated significant clinical benefits over a 3-year period in all SCA genotypes. - **Taldefgrobep Alfa**: Taldefgrobep alfa is a treatment for Spinal Muscular Atrophy (SMA) and obesity. It has shown promising results in clinical trials, including significant improvements in motor function and muscle mass in SMA patients. - **BHV-7000**: BHV-7000 is a selective Kv7 activator with potential applications in treating bipolar disorder, major depressive disorder, and epilepsy. - **BHV-2100**: BHV-2100 is a TRPM3 antagonist with potential applications in treating migraine and pain disorders. - **BHV-8000**: BHV-8000 is a brain-penetrant TYK2/JAK1 inhibitor with potential applications in treating Parkinson's disease, anti-amyloid therapy-induced ARIA, Alzheimer's disease, and multiple sclerosis. - **BHV-1400**: BHV-1400 is a Gd-IgA1 degrader with potential applications in treating IgA nephropathy. It has shown rapid, deep, and selective removal of Gd-IgA1 while preserving healthy immune function. - **BHV-1600**: BHV-1600 is a β1AR autoantibody degrader with potential applications in treating peripartum cardiomyopathy (PPCM). It has demonstrated selectivity and deep removal of β1AR autoantibodies while preserving immunity. - **BHV-1300**: BHV-1300 is an IgG degrader with potential applications in treating Graves' disease. It has shown promising results in clinical trials, including selective removal of TSHR-IgG1 autoantibodies. - **BHV-1510**: BHV-1510 is a Trop2 ADC with potential applications in treating advanced or metastatic epithelial tumors. It has demonstrated early clinical activity in phase 1 trials. - **BHV-1530**: BHV-1530 is a FGFR3 ADC with potential applications in treating urothelial cancer. It has shown synergistic activity in vivo with anti-PD-L1 combination. - **BHV-7000**: BHV-7000 is a Kv7.2/7.3 activator with potential applications in treating bipolar disorder, major depressive disorder, and epilepsy. It is nearing completion of pivotal trials with blockbuster potential. Other Important Content - **Market Potential**: Biohaven's degrader platform has a significant market potential, with peak US gross sales potential estimated at $15 billion for degraders and $8 billion for IgG degraders. - **Strategic Collaborations**: Biohaven has entered into strategic collaborations with Merus and GeneQuantum to develop next-generation ADCs and other therapies. - **Financial Updates**: Biohaven has potential royalties from Pfizer's rimegepant and zavegepant sales, with royalty payments expected to be in the low to mid-teens% range. - **Pipeline**: Biohaven's pipeline includes a diverse range of therapies targeting various diseases, with a focus on rare diseases, neurological disorders, oncology, and immunology and inflammation-related conditions.

Company and Industry Overview * **Company**: BioMarin Pharmaceutical Inc. * **Industry**: Biotechnology, specializing in treatments for genetically defined conditions. Key Financial Highlights * **Total Revenues**: $2.1 billion (3Q'24 YTD) * **Non-GAAP Operating Margin**: 27.7% * **Non-GAAP Diluted Earnings Per Share**: $2.60 * **Revenue Growth**: +19% YOY * **Operating Margin Growth**: +7.6 ppts YOY Pipeline and Pipeline Highlights * **VOXZOGO**: * Phase 3 data for 5 indications (achondroplasia, hypochondroplasia, idiopathic short stature, Noonan Syndrome, Turner Syndrome, SHOX deficiency) * Expansion into additional countries, including Europe, Japan, Australia, and Canada * Strong growth potential in the U.S. market * **Palynziq**: * Phase 3 data and U.S. & EU sBLA filings * Expansion of label to include 12-17 year-olds * Potential for $1.25B+ in 2027 operating cash flow * **BMN 390**: * First-in-human study start for PKU with novel PEG * **BMN 351**: * Clinical POC data for Duchenne Muscular Dystrophy * **BMN 349**: * Study start for alpha-1 antitrypsin deficiency * **BMN 370**: * First-in-human study start for von Willebrand disease Business Development and External Innovation * Focus on disciplined deal execution with a focus on Skeletal Conditions, Enzyme Therapies, and First in Genetic Conditions * Strong global commercial infrastructure and world-class research, clinical, and regulatory capabilities * Rich biotech arena with many small companies at R&D stage Financial Outlook * Revenue growth targeting mid-teen CAGR from 2023-2034 * Non-GAAP operating margin targeting 40% in 2027 * Non-GAAP operating cash flow targeting $1.25B+ in 2027 Other Important Points * BioMarin is the global leader in treating genetically defined conditions * Strong execution in 2024, with significant growth in revenues and operating margin * Focus on innovation and growth through a robust pipeline and strategic business development initiatives

Industry and Company Overview * **Industry**: Biotechnology and pharmaceuticals, focusing on rare and orphan diseases. * **Company**: BridgeBio Pharma, a clinical-stage biopharmaceutical company developing therapies for rare genetic diseases. Key Recent Achievements * **Clinical Impact**: * Publication of positive clinical trial results for Acoramidis (acoramidis) in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine. * Publication of positive clinical trial results for Infigratinib in Achondroplasia in the New England Journal of Medicine. * Publication of positive clinical trial results for Encaleret in Autosomal Dominant Hypocalcemia Type 1 in the New England Journal of Medicine. * **Regulatory Advancement**: * Infigratinib received Breakthrough Therapy Designation (BTD) for Achondroplasia. * BBP-418 received Rare Pediatric Disease Designation (RPDD) for Limb-Girdle Muscular Dystrophy 2I/R9. * BBP-812 received Regenerative Medicine Advanced Therapy Designation (RMAT) for Canavan Disease. * Approval of Acoramidis (acoramidis) for the treatment of adult patients with ATTR-CM. * **Commercial Momentum**: * Acoramidis (acoramidis) scripts have been written to date. * Positive feedback from payers and healthcare providers regarding Acoramidis (acoramidis) market access. Pipeline Programs * **Attruby (acoramidis)**: A treatment for ATTR-CM, with a global annual market sales of over $6.4 billion. * **Infigratinib**: A treatment for Achondroplasia and Hypochondroplasia, with a market opportunity of over $4 billion. * **BBP-418**: A treatment for Limb-Girdle Muscular Dystrophy 2I/R9, with a market opportunity of over $1 billion. * **Encaleret**: A treatment for Autosomal Dominant Hypocalcemia Type 1, with a market opportunity of over $2 billion. * **BBP-812**: A treatment for Canavan Disease, with a potential to change the disease trajectory for affected patients. * **BridgeBio Oncology Therapeutics**: A separate company focused on oncology therapies. * **GondolaBio**: A separate company focused on rare disease therapies. Financials and Future Outlook * BridgeBio Pharma is well-financed and expects to hit numerous milestones in 2025. * The company's vision for 2030 includes de-risking its pipeline, impacting over 100,000 lives, and achieving a market capitalization of over $8 billion.

Ascendis Pharma A/S J.P. Morgan Healthcare Conference San Francisco January 2025 For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements 1. Approved in the U.S., EU, and other territories, including Norway, Iceland, Liechtenstein, and Great Britain (covering England, Wales, Scotland). 2. Calculated as unaudited preliminary estimate of full year 2024 SKYTROFA revenue of ~€197 million plus ~€5 million of sales deductions re ...

Summary of Daiichi Sankyo's Conference Call Company Overview - **Company**: Daiichi Sankyo Co., Ltd. - **Date**: January 13, 2025 - **CEO**: Sunao Manabe Key Points Industry and Company Focus - **Industry**: Oncology, specifically focusing on Antibody-Drug Conjugates (ADCs) [8][9] - **Core Products**: ENHERTU®, DATROWAY®, HER3-DXd [53] Financial Performance - **FY2024 Consolidated P&L Overview**: - Revenue: 1,830.0 billion JPY, an increase of 228.3 billion JPY (+14.3% from FY2023) [9] - Cost of Sales: 410.0 billion JPY, a decrease of 4.8 billion JPY (-1.2%) [9] - SG&A Expenses: 700.0 billion JPY, an increase of 72.7 billion JPY (+11.6%) [9] - R&D Expenses: 460.0 billion JPY, an increase of 95.7 billion JPY (+26.3%) [9] - Core Operating Profit: 260.0 billion JPY, an increase of 64.7 billion JPY (+33.1%) [9] - Operating Profit: 280.0 billion JPY, an increase of 68.4 billion JPY (+32.4%) [9] - Profit Attributable to Owners: 225.0 billion JPY, an increase of 24.3 billion JPY (+12.1%) [9] Product Development and Approvals - **ADCs Development**: - 7 DXd ADCs from the DXd platform are currently in development [15] - ENHERTU® has received approvals for 5 indications, launched in over 60 countries, with expected annual sales exceeding 500 billion JPY in FY2024 [18][19] - Regulatory submissions for ENHERTU® based on DESTINY-Breast06 outcomes are under review in Japan, US, and EU [22] Strategic Collaborations - **Collaboration with AstraZeneca**: - Awarded the 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU® [16] - Collaboration enhances product value and clinical development opportunities [44] - **Collaboration with Merck**: - Strategic collaboration initiated in October 2023 for co-development and co-commercialization of HER3-DXd, I-DXd, and R-DXd [28] Shareholder Returns - **Shareholder Return Policy**: - Targeting ROE > 16% and DOE > 8% by FY2025 [51][52] - Plans to increase dividends for three consecutive years, considering profit growth [55] - Total acquisition cost for share buybacks is 200 billion JPY [57] Future Outlook - **5-Year Business Plan (FY2021-FY2025)**: - Aiming to become a global pharma innovator with a competitive advantage in oncology by 2025 [59][61] - Focus on sustainable growth and enhancing shareholder value [61][62] Additional Insights - **Digital Pathology Platform**: - Development of a digital pathology platform to enhance capabilities for upcoming products [39][40] - **Supply Capacity**: - Capital investment of approximately 600 billion JPY planned globally to meet peak demand for ADCs [48] This summary encapsulates the essential information from the conference call, highlighting the company's financial performance, product development, strategic collaborations, shareholder returns, and future outlook in the oncology sector.

Summary of BeiGene's Conference Call Company Overview - **Company**: BeiGene - **Industry**: Oncology and Hematology - **Event**: 4th Annual J.P. Morgan Healthcare Conference 2025 Key Points and Arguments Financial Performance - **Q3 2024 Cash Flow**: Generated $188 million in cash flow from operations, driven by improved operating leverage and working capital [10][11][134] - **Revenue Growth**: Product revenues grew by 67% in Q3 2024 compared to Q3 2023 [11] - **Quarterly Revenue**: Achieved $1 billion in quarterly revenue, with significant contributions from BRUKINSA [133] Product Leadership - **BRUKINSA**: - Currently the 1 BTK inhibitor (BTKi) in the U.S. for new Chronic Lymphocytic Leukemia (CLL) patients [10][11] - Holds the broadest label with approvals in 72 countries, covering multiple indications [34] - Expected to launch a new tablet formulation in 2025 [34] - **Pipeline**: - 13 new molecular entities (NMEs) entered the clinic in 2024 [10] - Focus on hematology leadership and advancing internally developed assets [21][72] Market Position and Strategy - **Market Share**: Positioned to capture significant market share in hematologic diseases, particularly in the $12 billion CLL market [10] - **Redomicile to Switzerland**: Anticipated to enhance global presence and operational efficiency, pending shareholder vote in early 2025 [10][126] - **Clinical Team**: A global clinical team of over 3,600 personnel, enabling independence from traditional CRO models [14] Industry Challenges - **R&D Returns**: The industry faces increasing trial costs, with oncology trial costs per patient rising from approximately $100,000 to $250,000-$300,000 [12] - **Regulatory Delays**: Project Optimus has delayed Phase 2 trials by 6-9 months, increasing patient numbers in Phase 1 trials by 50-100% [12] Future Focus - **2025 Goals**: - Solidify hematology leadership - Advance the pipeline of internally developed assets - Drive superior financial performance [21][72] - **Key Catalysts**: Anticipated data readouts and regulatory submissions for various assets, including BRUKINSA and Sonrotoclax [131][132] Competitive Landscape - **Emerging Therapies**: - BTK CDAC (Chimeric Degradation Activation Compound) is being positioned as a potential best-in-class approach, with a Phase 3 head-to-head trial against pirtobrutinib planned for 2025 [55][58] - Combination therapies with Sonrotoclax are expected to enhance treatment efficacy in CLL [52][61] Risk Factors - **Market Risks**: Potential pricing pressures from governmental regulations and competition from other therapies [12][36] - **Clinical Risks**: The efficacy and safety of drug candidates must be demonstrated to achieve marketing approval [4] Additional Important Information - **Clinical Data**: Some data presented are from early-phase trials and should be interpreted with caution [7][8] - **Forward-Looking Statements**: Actual results may differ materially from projections due to various factors, including regulatory actions and market conditions [4][5] This summary encapsulates the critical insights from BeiGene's conference call, highlighting its financial performance, product leadership, strategic focus, and the challenges faced within the oncology industry.

Summary of the Conference Call Company Overview - The conference was held at the 43rd Annual J.P. Morgan Healthcare Conference featuring Baxter's Chair, President & CEO, José (Joe) Almeida [1] Industry and Company Highlights - Baxter is undergoing a broad strategic transformation aimed at enhancing performance, accelerating innovation, and driving incremental value for stakeholders [9] - The company is finalizing the sale of its Kidney Care business, expected to close early 2025, with anticipated cash proceeds of approximately $3.50 billion [15] - Baxter restarted production at its North Cove, NC manufacturing facility, aiming to return to pre-Hurricane production levels by early Q1 2025 [9] Financial Outlook - Baxter provided preliminary guidance for 2025, targeting an adjusted operating margin of approximately 16.5% and operational sales growth of 4% to 5% annually [38] - The company aims for a free cash flow conversion ratio of around 80%, driven by improved operating results and working capital enhancements [38] - Baxter's capital allocation priorities include deleveraging to reach an investment-grade target of approximately 3.0X by the end of 2025 [38] Strategic Actions and Divestitures - The divestiture of the BioPharma Solutions business was completed at the end of Q3 2023, utilizing about $3.7 billion of net after-tax proceeds for debt repayment [13] - Baxter has transitioned to a new operating model, reporting across four global segments instead of nine businesses [11] Product Development and Innovation - Baxter is focused on customer-inspired innovation, with a diverse portfolio of medical products, therapies, healthcare systems, and pharmaceuticals [17] - The company is targeting around 10 new product launches per year in its pharmaceuticals segment [35] Risks and Forward-Looking Statements - The company highlighted various risks that could impact its financial performance, including global economic conditions, regulatory changes, and operational challenges [2] - Baxter does not provide reconciliations for forward-looking non-GAAP financial measures due to the unpredictability of certain factors [5] Conclusion - Baxter is positioned to enhance its agility and focus on growth and innovation through strategic transformations and divestitures, while navigating potential risks in the healthcare landscape [16]